As antiviral therapy becomes more widely available and management and control of chronic hepatitis B disease improves, patients’ demands for treatment are gradually increasing. More and more people want to treat chronic hepatitis B with a limited course of treatment rather than taking medication for life. Authoritative findings show that more than 90% of patients taking nucleoside analogs desire to discontinue the drug. According to current treatment guidelines, patients taking nucleoside analogs may attempt to discontinue the drug if e antigen seroconversion occurs and after a longer period of consolidation therapy. Fewer patients are clinically able to meet this criterion for discontinuation. Overall, the chances of e antigen conversion occurring after 1 year of treatment with all types of nucleoside analogs are no more than one in four, and the rate of e antigen conversion is less than 30% with continued treatment for 3-5 years. Furthermore, even when discontinued under these more stringent conditions, the relapse rate for nucleoside analogs remains high, with only one-third likely to be safely discontinued. This means that for the vast majority of patients treated with nucleoside analogs, they need to be prepared to take the drugs for a long time or even for life if they do not switch their treatment strategy. Nucleosides are susceptible to relapse when discontinued primarily because they are direct antivirals, and discontinuation of the drug terminates this effect, which manifests itself as disease relapse. Another class of antiviral drugs, long-acting interferon, in the direct antiviral at the same time can improve the body’s immunity, the body’s immunity will continue to fight the virus after stopping the drug, manifested as a long-lasting response to the discontinuation of the drug. A growing body of research and clinical experience has shown that long-acting interferon therapy in patients taking nucleoside analogs improves e-antigen conversion and surface antigen clearance. For example, a large-scale study showed that after 1 year of entecavir treatment, the e-antigen conversion rate was approximately 10% if treatment was continued for 1 year, and more than two-fold if long-acting interferon therapy was given after 1 year. The OSST study1 showed surface antigen clearance in 25% of patients. Long-acting interferon therapy is expected to help shorten the course of treatment and achieve safe discontinuation in patients who are on nucleoside analog therapy and are eager to stop. If HBV DNA conversion and e-antigen clearance are achieved during the course of treatment, it is important to pay special attention to the results of the full quantitative surface antigen test, and to seize the opportunity to switch to long-acting interferon in order to achieve safe discontinuation of the drug.